Physician profile
Sergey Zhivotenko
NPI 1154348092
$20,269.67
in general payments reported to CMS, 2019-2025
51 companies · $3,490 in 2025
The $3,490 reported for 2025 was more than what 81% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,939 · 2020: $1,903 · 2021: $3,166 · 2022: $3,221 · 2023: $3,324 · 2024: $3,226 · 2025: $3,490.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,907 · Education: $111 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,907.15 |
| Education | $111.49 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,548.91 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Neurelis, INC. | $1,502.03 | 2020-2025 | Valtoco |
| Eisai INC. | $1,402.67 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,298.86 | 2023-2025 | Rexulti, Nuedexta |
| Ucb, INC. | $1,164.15 | 2020-2025 | Briviact, Nayzilam |
| Amgen INC. | $1,080.54 | 2019-2025 | Aimovig, Uplizna |
| Neurocrine Biosciences, INC. | $981.17 | 2020-2025 | Ingrezza, Ongentys |
| Lilly USA, LLC | $895.72 | 2019-2025 | Amyvid, Emgality, Kisunla |
| Amneal Pharmaceuticals LLC | $773.97 | 2019-2025 | Rytary, Crexont, Ongentys |
| Axsome Therapeutics, INC. | $763.11 | 2023-2025 | Auvelity, Symbravo |
| Sk Life Science, INC. | $740.63 | 2020-2022 | |
| Avanir Pharmaceuticals, INC. | $693.82 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $693.07 | 2019-2022 | |
| Mdd US Operations, LLC | $639.45 | 2022-2025 | Gocovri, Apokyn, Gocovri |
| Allergan, INC. | $524.70 | 2019-2022 |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $521.85 | 2019-2025 | Nuplazid |
| Azurity Pharmaceuticals, INC. | $431.64 | 2023-2025 | Horizant, Horizant, Alvesco |
| Lundbeck LLC | $423.43 | 2024-2025 | Vyepti, Rexulti |
| Avion Pharmaceuticals | $409.88 | 2022-2023 | Dhivy |
| Biogen, INC. | $343.50 | 2020-2025 | Leqembi, Vumerity |
| Teva Pharmaceuticals USA, INC. | $322.39 | 2019-2025 | Austedo, Austedo Xr, Ajovy |
| Medtronic, INC. | $302.96 | 2021-2025 | Percept Pc Brainsense |
| Scilex Pharmaceuticals INC. | $275.06 | 2020-2025 | Ztlido |
| Pfizer INC. | $251.66 | 2019-2025 | |
| Biohaven Pharmaceuticals, INC. | $248.39 | 2021 | |
| Adamas Pharmaceuticals, INC. | $232.90 | 2020-2021 | |
| Genzyme Corporation | $175.18 | 2022-2023 | |
| Kyowa Kirin, INC. | $165.23 | 2021-2025 | Nourianz |
| Merck Sharp & Dohme LLC | $155.25 | 2020-2023 | Belsomra |
| Assertio Therapeutics, INC. | $147.22 | 2019-2020 | |
| Almatica Pharma LLC | $119.43 | 2021-2023 | Gralise |
| Acorda Therapeutics, INC | $114.47 | 2019 | |
| Horizon Therapeutics Plc | $109.36 | 2019-2022 | |
| Endo Pharmaceuticals INC. | $98.05 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $94.60 | 2019-2021 | |
| Bausch Health US, LLC | $70.06 | 2019-2020 | |
| Impel Pharmaceuticals INC. | $62.89 | 2023 | Trudhesa |
| Sunovion Pharmaceuticals INC. | $59.82 | 2022 | |
| Argenx US, INC. | $54.55 | 2024-2025 | Vyvgart Hytrulo |
| Si-Bone, INC. | $48.83 | 2019-2021 | |
| Catalyst Pharmaceuticals, INC. | $43.15 | 2021 | |
| Ge Healthcare | $43.14 | 2019-2022 | |
| Medtronic USA, INC. | $43.07 | 2020 | |
| Idorsia Pharmaceuticals US INC | $42.37 | 2023 | Quviviq |
| Vertical Pharmaceuticals, LLC | $41.82 | 2019 | |
| Tanabe Pharma America, INC. | $22.29 | 2023 | |
| Vanda Pharmaceuticals INC. | $20.99 | 2025 | Ponvory |
| Abbott Laboratories | $19.45 | 2023 | Infinity |
| Zyla Life Sciences, INC. | $17.50 | 2019 | |
| Alexion Pharmaceuticals, INC. | $17.42 | 2023 | Ultomiris |
| Biohaven Pharmaceutical Holding Company Ltd. | $17.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sergey Zhivotenko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.